Overview

• TTAM Research Institute topped Regeneron’s $256 million offer with a $305 million bid for 23andMe’s genetic testing and telehealth units
• The U.S. Bankruptcy Court for the Eastern District of Missouri will hold a hearing next week to decide on the asset sale
• Attorneys general in multiple states have lodged objections or filed lawsuits challenging the transfer of customer DNA records to TTAM
• An independent report commissioned by the court highlighted a 2023 breach that exposed data from about seven million accounts, with related litigation to be settled from sale proceeds
• Shares of 23andMe have climbed to $5.49 as investors anticipate resolution of bankruptcy proceedings and data liability issues